SCHEMBL1764609

SCHEMBL1764609

[2H]C([2H])([2H])C(c1cc(-c2ccc[nH]c2=O)cc(NC(=O)c2ccc(NS(C)(=O)=O)cn2)c1OC)(C([2H])([2H])[2H])C([2H])([2H])[2H]

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.53
ABL1 P00519 1/20 0.37
MAPK14 Q16539 3/20 0.36
MAPK10 P53779 1/20 0.36
PIK3CD O00329 2/20 0.35
CDC25A P30304 1/20 0.35
CDC25B P30305 1/20 0.35
PIK3CA P42336 1/20 0.35
PIK3CB P42338 1/20 0.35
PIK3CG P48736 1/20 0.35
CDK9 P50750 2/20 0.34
LYN P07948 1/20 0.33
MAPK9 P45984 1/20 0.33
TRPV1 Q8NER1 1/20 0.33
S1PR1 P21453 1/20 0.33
FYN P06241 1/20 0.33
TGFBR1 P36897 1/20 0.33
ACVR1 Q04771 1/20 0.33
PIP4K2A P48426 1/20 0.32
PIP4K2B P78356 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1542477 0.94 CYP3A4 (0.59) CYP3A4ABL1MAPK14MAPK10PIK3CD
SCHEMBL1542369 0.83 CYP3A4 (0.65) CYP3A4ABL1MAPK14MAPK10CDK9
SCHEMBL1542876 0.81 CYP3A4 (0.58) CYP3A4MAPK14TRPV1MEN1KMT2A
SCHEMBL1542928 0.80 CYP3A4 (0.44) CYP3A4ABL1CDC25ACDC25BMEN1
SCHEMBL2129460 0.80 CYP3A4 (0.59) CYP3A4ABL1MAPK14MAPK10TRPV1
SCHEMBL2127612 0.79 CYP3A4 (0.58) CYP3A4ABL1MAPK14TRPV1MEN1
SCHEMBL2128872 0.79 CYP3A4 (0.57) CYP3A4ABL1MAPK14TRPV1MEN1
SCHEMBL1542597 0.79 CYP3A4 (0.57) CYP3A4MAPK14TRPV1MEN1KMT2A
SCHEMBL1542475 0.78 CYP3A4 (0.56) CYP3A4MAPK14MEN1KMT2A
SCHEMBL2128420 0.77 CYP3A4 (0.53) CYP3A4MAPK14LYNMAPK9MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110123489-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS ROCHE PALO ALTO LLC (US) 2011-05-26 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110123489-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS HCCS, EIF2AK2, RNASE1 CYP3A4 60/4885ABL1 375/4885MAPK14 4100/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.